Pharvaris N.V.
Developing oral therapies for rare angioedema to treat and prevent attacks.
PHVS | NDAQ
Overview
Corporate Details
- ISIN(s):
- NL00150005Y4
- LEI:
- Country:
- United States of America
- Address:
- J.H. OORTWEG 21, 0 LEIDEN
- Website:
- https://pharvaris.com/
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
Pharvaris N.V. is a late-stage clinical biopharmaceutical company focused on the development and commercialization of therapies for rare, bradykinin-mediated diseases. The company is developing novel, oral bradykinin B2 receptor antagonists to treat and prevent attacks in patients with hereditary angioedema (HAE) and acquired angioedema (AAE). Its lead product candidate, deucrictibant, is in pivotal Phase 3 studies for both on-demand and prophylactic treatment. Pharvaris aims to provide an alternative to injectable treatments by offering an oral therapy with injectable-like efficacy and a favorable tolerability profile, seeking to improve the quality of life and treatment options for patients.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all Pharvaris N.V. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Pharvaris N.V.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Pharvaris N.V. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
